6-KThe Wire
Alvotech files 6-K
Filed Feb 5, 2026 · 5mo ago · Accession 0001171843-26-000641
Plain English
Alvotech announced positive top-line results from a pharmacokinetic study for its biosimilar candidate AVT80, which met all primary endpoints. The study compared AVT80 to Entyvio® (vedolizumab) in healthy adult participants.
Filing details
- Company
- Alvotech
- Ticker
- ALVO
- CIK
- 1898416
- Form type
- 6-K
- Filing date
- Feb 5, 2026
- Report date
- Feb 5, 2026
- Document
- f6k_020526.htm
- Size
- 17 KB